首页> 美国卫生研究院文献>Virology Journal >A catalytically and genetically optimized β-lactamase-matrix based assay for sensitive specific and higher throughput analysis of native henipavirus entry characteristics
【2h】

A catalytically and genetically optimized β-lactamase-matrix based assay for sensitive specific and higher throughput analysis of native henipavirus entry characteristics

机译:催化和遗传优化的基于β-内酰胺酶-基质的检测方法用于天然肝炎病毒进入特征的灵敏特异和高通量分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nipah virus (NiV) and Hendra virus (HeV) are the only paramyxoviruses requiring Biosafety Level 4 (BSL-4) containment. Thus, study of henipavirus entry at less than BSL-4 conditions necessitates the use of cell-cell fusion or pseudotyped reporter virus assays. Yet, these surrogate assays may not fully emulate the biological properties unique to the virus being studied. Thus, we developed a henipaviral entry assay based on a β-lactamase-Nipah Matrix (βla-M) fusion protein. We first codon-optimized the bacterial βla and the NiV-M genes to ensure efficient expression in mammalian cells. The βla-M construct was able to bud and form virus-like particles (VLPs) that morphologically resembled paramyxoviruses. βla-M efficiently incorporated both NiV and HeV fusion and attachment glycoproteins. Entry of these VLPs was detected by cytosolic delivery of βla-M, resulting in enzymatic and fluorescent conversion of the pre-loaded CCF2-AM substrate. Soluble henipavirus receptors (ephrinB2) or antibodies against the F and/or G proteins blocked VLP entry. Additionally, a Y105W mutation engineered into the catalytic site of βla increased the sensitivity of our βla-M based infection assays by 2-fold. In toto, these methods will provide a more biologically relevant assay for studying henipavirus entry at less than BSL-4 conditions.
机译:尼帕病毒(NiV)和亨德拉病毒(HeV)是唯一需要生物安全等级4(BSL-4)遏制的副粘病毒。因此,在少于BSL-4条件下研究肝炎病毒进入需要使用细胞-细胞融合或假型报告基因病毒测定。但是,这些替代检测可能无法完全模仿所研究病毒独有的生物学特性。因此,我们开发了一种基于β-内酰胺酶-Nipah基质(βla-M)融合蛋白的肝炎病毒进入试验。我们首先对细菌的βla和NiV-M基因进行了密码子优化,以确保在哺乳动物细胞中的有效表达。 βla-M构建体能够萌芽并形成形态类似于副粘病毒的病毒样颗粒(VLP)。 βla-M有效整合了NiV和HeV融合糖蛋白和附着糖蛋白。这些VLP的进入通过βla-M的胞质传递来检测,从而导致预载CCF2-AM底物的酶促和荧光转化。可溶性肝炎病毒受体(ephrinB2)或针对F和/或G蛋白的抗体可阻止VLP进入。此外,改造成βla催化位点的Y105W突变使我们基于βla-M的感染检测的灵敏度提高了2倍。总而言之,这些方法将为在小于BSL-4条件下研究肝炎病毒进入提供更生物学相关的测定方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号